Payment overview · 2025
General Payments
$346.56
18 reported records · 10 companies
Healthcare provider profile · identity verified
Zafer Obeid, M.D
Allopathic & Osteopathic Physicians|Internal Medicine · DEARBORN, MI · NPI 1255499257
Verified facts
What the public records show
CMS Open Payments records show Zafer Obeid, M.D received $346.56 in general payments during 2025 across 18 reported records.
AstraZeneca Pharmaceuticals LP accounted for 21.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 13 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Synthroid by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 172 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 85 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 277 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 92 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 130 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $73.43 | 21.2% | 4 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $65.97 | 19.0% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $56.61 | 16.3% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $30.39 | 8.8% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $30.13 | 8.7% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $21.09 | 6.1% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $18.41 | 5.3% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $18.38 | 5.3% | 1 | 2025 |
| Tonix Medicines, Inc. | Unresolved — no canonical attribution shown | $17.76 | 5.1% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $14.39 | 4.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $346.56 | 18 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $65.97 | 3 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $56.61 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $42.60 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $30.83 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $30.39 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $30.13 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $30.13 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $21.09 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $18.41 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $18.38 | 1 | 2025 |
Source payment records
|
|||||
| TONMYA Normalized: tonmya |
Drug | Tonix Medicines, Inc. | $17.76 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $15.24 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $14.39 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 277 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 85 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
38 | 23 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
172 | 27 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
85 | 12 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
277 | 44 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
40 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
92 | 16 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
56 | 11 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
130 | 21 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 761 | 127 |
| Losartan Potassium | Losartan Potassium | 740 | 109 |
| Metformin Hcl | Metformin Hcl | 718 | 110 |
| Omeprazole | Omeprazole | 664 | 99 |
| Amlodipine Besylate | Amlodipine Besylate | 623 | 97 |
| Metoprolol Succinate | Metoprolol Succinate | 505 | 70 |
| Levothyroxine Sodium | Levothyroxine Sodium | 396 | 65 |
| Diclofenac Sodium | Diclofenac Sodium | 364 | 81 |
| Tamsulosin Hcl | Tamsulosin Hcl | 341 | 51 |
| Celecoxib | Celecoxib | 336 | 61 |
| Fluticasone Propionate | Fluticasone Propionate | 327 | 59 |
| Pantoprazole Sodium | Pantoprazole Sodium | 314 | 54 |
| Ibuprofen | Ibuprofen | 308 | 66 |
| Tizanidine Hcl | Tizanidine Hcl | 280 | 83 |
| Jardiance | Empagliflozin | 277 | 44 |
| Lisinopril | Lisinopril | 271 | 44 |
| Allopurinol | Allopurinol | 268 | 44 |
| Hydralazine Hcl | Hydralazine Hcl | 267 | 36 |
| Lovastatin | Lovastatin | 233 | 35 |
| Alendronate Sodium | Alendronate Sodium | 217 | 32 |
| Simvastatin | Simvastatin | 213 | 30 |
| Pregabalin | Pregabalin | 197 | 24 |
| Glimepiride | Glimepiride | 191 | 23 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 187 | 32 |
| Gabapentin | Gabapentin | 186 | 34 |
| Meloxicam | Meloxicam | 179 | 29 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 175 | 30 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 173 | 38 |
| Dicyclomine Hcl | Dicyclomine Hcl | 172 | 42 |
| Farxiga | Dapagliflozin Propanediol | 172 | 27 |
| Clopidogrel | Clopidogrel Bisulfate | 160 | 26 |
| Metoprolol Tartrate | Metoprolol Tartrate | 157 | 26 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 147 | 42 |
| Tradjenta | Linagliptin | 145 | 21 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 143 | 25 |
| Hydrochlorothiazide | Hydrochlorothiazide | 140 | 24 |
| Ammonium Lactate | Ammonium Lactate | 133 | 18 |
| Famotidine | Famotidine | 132 | 18 |
| Eliquis | Apixaban | 130 | 21 |
| Trazodone Hcl | Trazodone Hcl | 128 | 29 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 126 | 21 |
| Meclizine Hcl | Meclizine Hcl | 122 | 29 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 119 | 23 |
| Furosemide | Furosemide | 118 | 22 |
| Gemfibrozil | Gemfibrozil | 110 | 19 |
| Azithromycin | Azithromycin | 108 | 74 |
| Tramadol Hcl | Tramadol Hcl | 108 | 31 |
| Clonazepam | Clonazepam | 107 | 15 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 103 | 22 |
| Hydrocortisone | Hydrocortisone | 98 | 22 |
| Prednisone | Prednisone | 97 | 66 |
| Carvedilol | Carvedilol | 92 | 21 |
| Trulicity | Dulaglutide | 92 | 16 |
| Ketoconazole | Ketoconazole | 89 | 18 |
| Duloxetine Hcl | Duloxetine Hcl | 88 | 12 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 85 | 12 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 84 | 12 |
| Fenofibrate | Fenofibrate Nanocrystallized | 83 | 11 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 83 | 19 |
| Zolpidem Tartrate | Zolpidem Tartrate | 79 | 21 |
| Escitalopram Oxalate | Escitalopram Oxalate | 74 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 72 | 26 |
| Sertraline Hcl | Sertraline Hcl | 68 | 12 |
| Januvia | Sitagliptin Phosphate | 64 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 63 | 12 |
| Dexlansoprazole Dr | Dexlansoprazole | 62 | suppressed |
| Mupirocin | Mupirocin | 62 | 29 |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 61 | 15 |
| Ventolin Hfa | Albuterol Sulfate | 60 | 15 |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 57 | suppressed |
| Procto-Med Hc | Hydrocortisone | 57 | suppressed |
| Ozempic | Semaglutide | 56 | 11 |
| Fluoxetine Hcl | Fluoxetine Hcl | 55 | 11 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 53 | suppressed |
| Glipizide | Glipizide | 50 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 49 | 11 |
| Propranolol Hcl | Propranolol Hcl | 48 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 47 | 28 |
| Clotrimazole | Clotrimazole | 46 | 13 |
| Ibu | Ibuprofen | 46 | 11 |
| Spironolactone | Spironolactone | 46 | suppressed |
| Lorazepam | Lorazepam | 45 | 11 |
| Montelukast Sodium | Montelukast Sodium | 44 | suppressed |
| Atenolol | Atenolol | 43 | suppressed |
| Valsartan | Valsartan | 42 | suppressed |
| Potassium Chloride | Potassium Chloride | 41 | suppressed |
| Mounjaro | Tirzepatide | 40 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 40 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 39 | 13 |
| Alprazolam | Alprazolam | 38 | suppressed |
| Finasteride | Finasteride | 38 | suppressed |
| Linzess | Linaclotide | 38 | suppressed |
| Mirtazapine | Mirtazapine | 38 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 38 | suppressed |
| Prolia | Denosumab | 38 | 23 |
| Jentadueto | Linagliptin/Metformin Hcl | 37 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 36 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 34 | suppressed |
| Lidocaine | Lidocaine | 33 | suppressed |
| Xarelto | Rivaroxaban | 33 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 32 | 28 |
| Fenofibrate | Fenofibrate | 32 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 31 | suppressed |
| Cephalexin | Cephalexin | 30 | 19 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 30 | suppressed |
| Metronidazole | Metronidazole | 30 | 22 |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 30 | suppressed |
| Amoxicillin | Amoxicillin | 29 | 21 |
| Colchicine | Colchicine | 29 | suppressed |
| Loperamide | Loperamide Hcl | 29 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 29 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 28 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 27 | suppressed |
| Ramipril | Ramipril | 27 | suppressed |
| Ranolazine Er | Ranolazine | 27 | suppressed |
| Methimazole | Methimazole | 25 | suppressed |
| Neomycin-Polymyxin-Hydrocort | Neomycin/Polymyxin B/Hydrocort | 25 | 23 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 24 | suppressed |
| Alcohol Swabs | Alcohol Antiseptic Pads | 24 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 24 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 24 | suppressed |
| Fluconazole | Fluconazole | 24 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 24 | suppressed |
| Topiramate | Topiramate | 24 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 23 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 23 | suppressed |
| Digoxin | Digoxin | 23 | suppressed |
| Lansoprazole | Lansoprazole | 23 | suppressed |
| Nifedipine Er | Nifedipine | 23 | suppressed |
| Nystatin | Nystatin | 23 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 23 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 22 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 22 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 22 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 22 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 21 | 15 |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 21 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Kerendia | Finerenone | 21 | suppressed |
| Novolog Flexpen | Insulin Aspart | 21 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 21 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 19 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 19 | 14 |
| Proctozone-Hc | Hydrocortisone | 19 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 19 | suppressed |
| Acyclovir | Acyclovir | 18 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 18 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Glipizide Er | Glipizide | 18 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 18 | suppressed |
| Erythromycin | Erythromycin Base | 17 | suppressed |
| Single Use Swab | Alcohol Antiseptic Pads | 17 | suppressed |
| Baclofen | Baclofen | 16 | suppressed |
| Brilinta | Ticagrelor | 16 | suppressed |
| Clonidine | Clonidine | 16 | suppressed |
| Dutasteride | Dutasteride | 16 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 15 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 15 | suppressed |
| Bupropion Xl | Bupropion Hcl | 14 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 14 | suppressed |
| Entresto | Sacubitril/Valsartan | 14 | suppressed |
| Glyburide | Glyburide | 14 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 14 | 13 |
| Synjardy | Empagliflozin/Metformin Hcl | 14 | suppressed |
| Bumetanide | Bumetanide | 13 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 13 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 13 | 11 |
| Desloratadine | Desloratadine | 13 | suppressed |
| Latanoprost | Latanoprost | 13 | suppressed |
| Naproxen | Naproxen | 13 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 13 | suppressed |
| Synthroid | Levothyroxine Sodium | 13 | suppressed |
| Toviaz | Fesoterodine Fumarate | 13 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 13 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 13 | suppressed |
| Zafirlukast | Zafirlukast | 13 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 12 | suppressed |
| Cilostazol | Cilostazol | 12 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 12 | suppressed |
| Diclofenac Sodium-Misoprostol | Diclofenac Sodium/Misoprostol | 12 | suppressed |
| Levetiracetam | Levetiracetam | 12 | suppressed |
| Levofloxacin | Levofloxacin | 12 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 12 | suppressed |
| Oxycontin | Oxycodone Hcl | 12 | suppressed |
| Selenium Sulfide | Selenium Sulfide | 12 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 12 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 11 | suppressed |
| Flunisolide | Flunisolide | 11 | suppressed |
| Indomethacin | Indomethacin | 11 | suppressed |
| Neomycin-Polymyxin-Hc | Neomycin/Polymyxin B/Hydrocort | 11 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 11 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 11 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 11 | suppressed |
| Sucralfate | Sucralfate | 11 | suppressed |
| Trijardy Xr | Empaglifloz/Linaglip/Metformin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $346.56 · 18 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, BREZTRI, Cologuard Collection Kit, JARDIANCE, NURTEC ODT, OTEZLA, REPATHA, TONMYA, TRELEGY ELLIPTA, UBRELVY, Wegovy, XIFAXAN, ZAVZPRET | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error